학술논문
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Document Type
Article
Author
Horwitz, Steven; O'Connor, Owen A; Pro, Barbara; Illidge, Tim; Fanale, Michelle; Advani, Ranjana; Bartlett, Nancy L; Christensen, Jacob Haaber; Morschhauser, Franck; Domingo-Domenech, Eva; Rossi, Giuseppe; Kim, Won Seog; Feldman, Tatyana; Lennard, Anne; Belada, David; Illés, Árpád; Tobinai, Kensei; Tsukasaki, Kunihiro; Yeh, Su-Peng; Shustov, Andrei; Hüttmann, Andreas; Savage, Kerry J; Yuen, Sam; Iyer, Swaminathan; Zinzani, Pier Luigi; Hua, Zhaowei; Little, Meredith; Rao, Shangbang; Woolery, Joseph; Manley, Thomas; Trümper, Lorenz; Aboulafia, David; Advani, Ranjana; Alpdogan, Onder; Ando, Kiyoshi; Arcaini, Luca; Baldini, Luca; Bellam, Naresh; Bartlett, Nancy; Belada, David; Yehuda, Dina Ben; Benedetti, Fabio; Borchman, Peter; Bordessoule, Dominique; Brice, Pauline; Briones, Javier; Caballero, Dolores; Carella, Angelo Michele; Chang, Hung; Cheong, June Weon; Cho, Seok-Goo; Choi, Ilseung; Choquet, Sylvain; Colita, Andrei; Congui, Angela Giovanna; D'amore, Francesco; Dang, Nam; Davison, Kelly; de Guibert, Sophie; Brown, Peter de Nully; Delwail, Vincent; Demeter, Judit; di Raimondo, Francesco; Do, Young Rok; Domingo, Eva; Douvas, Michael; Dreyling, Martin; Ernst, Thomas; Fanale, Michelle; Fay, Keith; Feldman, Tatyana; Ferrero, Silvia Fernandez; Flinn, Ian Winchester; Forero-Torres, Andres; Fox, Christopher; Friedberg, Jonathan; Fukuhara, Noriko; Garcia-Marco, Jose; Cruz, Jorge Gayoso; Codina, Jose Gomez; Gressin, Remy; Grigg, Andrew; Gurion, Ronit; Christensen, Jacob Haaber; Haioun, Corinne; Hajek, Roman; Hanel, Mathias; Hatake, Kiyohiko; Hensen, Robert; Horowitz, Netanel; Horwitz, Steven; Huttmann, Andreas; Illes, Arpad; Illidge, Tim; Ishizawa, Kenichi; Islas-Ohlmayer, Miguel; Jacobsen, Eric; Janakiram, Murali; Jurczak, Wojciech; Kaminski, Mark; Kato, Koji; Kim, Won Seog; Kirgner, Ilya; Iyer, Swaminathan; Kuo, Ching-Yuan; Lazaroiu, Mihaela Cornelia; Du, Katell Le; Lee, Jong-Seok; LeGouill, Steven; Lennard, Anne; LaRosee, Paul; Levi, Itai; Link, Brian; Maisonneuve, Herve; Maruyama, Dai; Mayer, Jiri; McCarty, John; McKay, Pam; Minami, Yosuke; Mocikova, Heidi; Morra, Enrica; Morschhauser, Franck; Munoz, Javier; Nagai, Hirokazu; O'Connor, Owen; Opat, Stephen; Pettengell, Ruth; Pezzutto, Antonio; Pfreundschuh, Michael; Pluta, Andrzej; Porcu, PierLuigi; Pro, Barbara; Quach, Hang; Rambaldi, Alessandro; Renwick, William; Reyes, Ruben; Izquierdo, Antonia Rodriguez; Rossi, Giuseppe; Ruan, Jia; Rusconi, Chiara; Salles, Gilles; Santoro, Armando; Sarriera, Jose; Savage, Kerry; Shibayama, Hirohiko; Shustov, Andrei; Suh, Cheolwon; Sureda, Anna; Tanimoto, Mitsune; Taniwaki, Masafumi; Tilly, Herve; Tobinai, Kensei; Trneny, Marek; Trumper, Lorenz; Tsukamoto, Norifumi; Tsukasaki, Kunihiro; Vitolo, Umberto; Walewski, Jan; Weidmann, Eckhart; Wilhelm, Martin; Witzens-Harig, Mathias; Yacoub, Abdulraheem; Yamamoto, Kazuhito; Yeh, Su-Peng; Yoon, Sung-Soo; Yuen, Sam; Yun, Hwan Jung; Zain, Jasmine; Zinzani, Pier Luigi
Source
The Lancet; January 2019, Vol. 393 Issue: 10168 p229-240, 12p
Subject
Language
ISSN
01406736; 1474547X
Abstract
Based on the encouraging activity and manageable safety profile observed in a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) versus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of CD30-positive peripheral T-cell lymphomas.